Edesa Biotech, Inc.
EDSA · XNASCIK 1540159fmd_0G75Q7WKW61H20MBJHVH515FEAManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Sep 01, 2011 to Jun 30, 2026, 53 periods
Latest annual · FY2021
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (8)
- Net income
- (7)
Latest quarter · Q3 FY2026
Millions- Operating income
- (6)
- Net income
- (5)
Daily close · EDSAIEX trades only
Aug 07, 2025 to Nov 11, 2026 · 250 sessions2.29 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
Edesa Biotech, Inc. (EDSA) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$7.9 million | -$7 million | 10-K 2025-12-12 · proof | |
| Net income | -$7.2 million | -$6.2 million | 10-K 2025-12-12 · proof | |
| Cash from operating activities | -$7.3 million | -$4.9 million | 10-K 2025-12-12 · proof | |
| Total assets | $13.5 million | $3.8 million | +254.8% | 10-K 2025-12-12 · proof |
| Total liabilities | $1.1 million | $1.8 million | -41.2% | 10-K 2025-12-12 · proof |
| Cash and cash equivalents | $10.8 million | $1 million | +980% | 10-K 2025-12-12 · proof |
- What was Edesa Biotech, Inc. (EDSA)'s operating income in fiscal 2025?
- Edesa Biotech, Inc. (EDSA) reported operating income of -$7.9 million for fiscal 2025 (the year ended Sep 30, 2025), against -$7 million the year before. Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
- What was Edesa Biotech, Inc. (EDSA)'s net income in fiscal 2025?
- Edesa Biotech, Inc. (EDSA) reported net income of -$7.2 million for fiscal 2025 (the year ended Sep 30, 2025), against -$6.2 million the year before. Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
- What was Edesa Biotech, Inc. (EDSA)'s cash from operating activities in fiscal 2025?
- Edesa Biotech, Inc. (EDSA) reported cash from operating activities of -$7.3 million for fiscal 2025 (the year ended Sep 30, 2025), against -$4.9 million the year before. Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
- What are Edesa Biotech, Inc. (EDSA)'s total assets?
- As of Sep 30, 2025, Edesa Biotech, Inc. (EDSA) reported total assets of $13.5 million, against $3.8 million a year earlier (+254.8%). Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
- What are Edesa Biotech, Inc. (EDSA)'s total liabilities?
- As of Sep 30, 2025, Edesa Biotech, Inc. (EDSA) reported total liabilities of $1.1 million, against $1.8 million a year earlier (-41.2%). Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
- What are Edesa Biotech, Inc. (EDSA)'s cash and cash equivalents?
- As of Sep 30, 2025, Edesa Biotech, Inc. (EDSA) reported cash and cash equivalents of $10.8 million, against $1 million a year earlier (+980%). Source: the 10-K filed with the SEC on Dec 12, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:EDSA&period_type=annual&limit=5"Information only, not investment advice.